The four companies will work out of the Ion's coworking space. Rendering courtesy of Common Desk

A new program has tapped four Houston startups and invited them to work out of the Ion surrounded and supported by fellow tech entrepreneurs.

The Ion's Onramp program, launched in July of this year, selects a handful of startups to operate out of the innovation hub's coworking space operated by Common Desk. Patenteer, Sensytec, Bridge Energy Solutions, and Stratos Perception will begin the program in January, according to a release from the Ion.

"These startups were selected due to the strength of their focus on leading digital transformation and leveraging technology to solve challenges that affect numerous industries in Houston," says Jan E. Odegard, executive director of the Ion, in the release. "Solving these challenges—which include commercializing research from Houston's academic institutions, developing resilient and robust infrastructure, leading the clean and sustainable energy transition, and propelling future aerospace advancements—is integral to Houston's success."

It's the second round of the program, and these four companies will be joining the first cohort, which includes Roxie Health, SpeakHaus, SUNN, and Justli. While not an accelerator, the eight companies receive up to 18 months of discounted shared desk membership, pitch practice, access to weekly programming, and one-on-one mentorship from Christine Galib, senior director of entrepreneurship and innovation.

"Selected startups in the first and second cohorts not only feature amazing startups but also represent Houston's diversity," says Odegard in the release. "We still have work to do, but we are making strides as we add the startups in the second cohort to the program.

"In the first six months, Cohort One startups have achieved notable accomplishments, including acquiring new clients and driving business development, designing revamped dashboards and prototypes, raising five-figure sums, taking first place at a national pitch competition, and securing selection into DivInc's first Women in Tech Accelerator," he continues.

The program intends to have a new cohort every six months and is looking for startups currently or planning to raise a pre-seed, seed, or series round of funding.

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Axiom Space-tested cancer drug advances to clinical trials

mission critical

A cancer-fighting drug tested aboard several Axiom Space missions is moving forward to clinical trials.

Rebecsinib, which targets a cancer cloning and immune evasion gene, ADAR1, has received FDA approval to enter clinical trials under active Investigational New Drug (IND) status, according to a news release. The drug was tested aboard Axiom Mission 2 (Ax-2) and Axiom Mission 3 (Ax-3). It was developed by Aspera Biomedicine, led by Dr. Catriona Jamieson, director of the UC San Diego Sanford Stem Cell Institute (SSCI).

The San Diego-based Aspera team and Houston-based Axiom partnered to allow Rebecsinib to be tested in microgravity. Tumors have been shown to grow more rapidly in microgravity and even mimic how aggressive cancers can develop in patients.

“In terms of tumor growth, we see a doubling in growth of these little mini-tumors in just 10 days,” Jamieson explained in the release.

Rebecsinib took part in the patient-derived tumor organoid testing aboard the International Space Station. Similar testing is planned to continue on Axiom Station, the company's commercial space station that's currently under development.

Additionally, the drug will be tested aboard Ax-4 under its active IND status, which was targeted to launch June 25.

“We anticipate that this monumental mission will inform the expanded development of the first ADAR1 inhibitory cancer stem cell targeting drug for a broad array of cancers," Jamieson added.

According to Axiom, the milestone represents the potential for commercial space collaborations.

“We’re proud to work with Aspera Biomedicines and the UC San Diego Sanford Stem Cell Institute, as together we have achieved a historic milestone, and we’re even more excited for what’s to come,” Tejpaul Bhatia, the new CEO of Axiom Space, said in the release. “This is how we crack the code of the space economy – uniting public and private partners to turn microgravity into a launchpad for breakthroughs.”